Aegis Capital Starts Can-Fite BioPharma (CANF) at Buy

June 24, 2021 10:24 AM EDT
Get Alerts CANF Hot Sheet
Price: $2.04 -3.32%

Rating Summary:
    2 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 27 | New: 42
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Aegis Capital analyst Christian Anketell initiates coverage on Can-Fite BioPharma (NYSE: CANF) with a Buy rating and a price target of $5.00.

Analyst comments: "
We expect several catalysts to drive the stock over the next 12 months which include 1.) the top-line results in 4Q 2021 from the ongoing Phase III study for Piclidenoson for psoriasis; 2.) the advancement of Namodenoson to Phase III clinical trial by end of 2021 for liver cancer treatment; 3.) the expansion of these drug treatments to other indications; 4.) continuing to sign exclusive distribution agreements, 5.) advancing through the cannabinoid program."

For an analyst ratings summary and ratings history on Can-Fite BioPharma click here. For more ratings news on Can-Fite BioPharma click here.

Shares of Can-Fite BioPharma closed at $2.20 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage